Efficacy of Preserved Tafluprost 0.0015% in Lowering Intraocular Pressure

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2023 Nov 22

PMID 37991299

Authors

Chandrima Paul

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the intraocular pressure (IOP) lowering effect of topical preserved tafluprost 0.0015% in a tertiary hospital setting in India.

Methods: This is a retrospective chart review of patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) attending regular outpatient visits in December 2019 and January 2021, and treated with topical preserved tafluprost 0.0015%. Based on their medication history, patients were divided into two groups, the "treatment naïve" group and the "switched" group, which included patients switched to tafluprost monotherapy after treatment with at least one prior drug.

Results: The mean IOP of the study population reduced significantly from baseline level by 20.6% and 25.5% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The mean IOP in patients with only OHT reduced significantly from baseline level by 21% and 26% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The mean IOP in patients with POAG reduced significantly from baseline level by 19% and 24% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The baseline IOP ± SD in POAG treatment naïve patients was 25.3 ± 0.3 mmHg, which reduced significantly by 24% and 28% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The baseline IOP ± SD in POAG switched patients was 24.3 ± 0.1 mmHg, which reduced significantly by 18% and 22% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). In the POAG switch group, the percent reduction in IOP at 3 months after preserved tafluprost 0.0015% treatment was 23% with timolol as first line, 22% with bimatoprost as first line, 20% with latanoprost as first line, and 19% with travoprost as first line (P < 0.001 for all).

Conclusions: We show significant IOP reduction with preserved tafluprost 0.0015% in a real-world setting. As first-line monotherapy in patients with OHT and in POAG-naïve patients, preserved tafluprost 0.0015% significantly reduced IOP at 3 months. Even as second-line therapy in nonresponders (POAG-Switched) to various drugs (same class [PGAs] versus different class), treatment with preserved tafluprost 0.0015% resulted in significant IOP reduction at 3 months.

References

Chabi A, Baranak C, Lupinacci R, Herring W . Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. Int J Clin Pract. 2016; 70(7):577-86. DOI: 10.1111/ijcp.12815. View

Uusitalo H, Pillunat L, Ropo A . Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010; 88(1):12-9. DOI: 10.1111/j.1755-3768.2010.01862.x. View

Tumbocon J, Macasaet A . Efficacy and safety of tafluprost 0.0015% - retrospective analysis of real-world data from the Philippines. Clin Ophthalmol. 2019; 13:1627-1634. PMC: 6717730. DOI: 10.2147/OPTH.S209942. View

. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021; 105(Suppl 1):1-169. DOI: 10.1136/bjophthalmol-2021-egsguidelines. View

. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000; 130(4):429-40. DOI: 10.1016/s0002-9394(00)00538-9. View

Ikeda Y, Mori K, Tada K, Ueno M, Kinoshita S, Sotozono C . Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clin Ophthalmol. 2016; 10:1633-7. PMC: 5003551. DOI: 10.2147/OPTH.S108213. View

Gupta S, Niranjan D G, Agrawal S, Srivastava S, Saxena R . Recent advances in pharmacotherapy of glaucoma. Indian J Pharmacol. 2009; 40(5):197-208. PMC: 2792620. DOI: 10.4103/0253-7613.44151. View

Traverso C, Ropo A, Papadia M, Uusitalo H . A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010; 26(1):97-104. DOI: 10.1089/jop.2009.0066. View

Harasymowycz P, Birt C, Gooi P, Heckler L, Hutnik C, Jinapriya D . Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol. 2016; 2016:6509809. PMC: 5118538. DOI: 10.1155/2016/6509809. View

10.

Kass M, Gordon M, Gao F, Heuer D, Higginbotham E, Johnson C . Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010; 128(3):276-87. PMC: 3966140. DOI: 10.1001/archophthalmol.2010.20. View

11.

George R, S Ve R, Vijaya L . Glaucoma in India: estimated burden of disease. J Glaucoma. 2010; 19(6):391-7. DOI: 10.1097/IJG.0b013e3181c4ac5b. View

12.

Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman D . Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2015; 123(1):129-40. PMC: 4695285. DOI: 10.1016/j.ophtha.2015.09.005. View

13.

Narayanaswamy A, Baskaran M, Zheng Y, Lavanya R, Wu R, Wong W . The prevalence and types of glaucoma in an urban Indian population: the Singapore Indian Eye Study. Invest Ophthalmol Vis Sci. 2013; 54(7):4621-7. DOI: 10.1167/iovs.13-11950. View

14.

Saxena R, Singh D, Vashist P . Glaucoma: an emerging peril. Indian J Community Med. 2013; 38(3):135-7. PMC: 3760320. DOI: 10.4103/0970-0218.116348. View

15.

Paul C, Sengupta S, Choudhury S, Banerjee S, Sleath B . Prevalence of glaucoma in Eastern India: The Hooghly River Glaucoma Study. Indian J Ophthalmol. 2016; 64(8):578-83. PMC: 5056545. DOI: 10.4103/0301-4738.191497. View

16.

Hamacher T, Airaksinen J, Saarela V, Liinamaa M, Richter U, Ropo A . Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf ). 2008; 242:14-9. DOI: 10.1111/j.1755-3768.2008.01381.x. View

17.

Leske M, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E . Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1):48-56. DOI: 10.1001/archopht.121.1.48. View

18.

Ge J, Li X, Sun X, He X, Zhang H . [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. Zhonghua Yan Ke Za Zhi. 2015; 51(2):95-102. View

19.

Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y . Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004; 78(4):767-76. DOI: 10.1016/j.exer.2003.12.007. View

20.

Keating G . Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension. Clin Drug Investig. 2016; 36(6):499-508. DOI: 10.1007/s40261-016-0413-z. View